Professor Mike Sharland is one of the UK and Europe’s leading experts in antimicrobial prescribing, resistance and healthcare associated infection in children.
He chairs the Department of Health’s Expert Advisory Body on antimicrobial resistance and healthcare associated infection (ARHAI). He is the paediatric advisor on the ECDC expert committee ESAC-net and the joint ECDC/CDC Transatlantic Task Force of Antimicrobial Resistance (TATFAR). He is the lead clinical advisor to the BNF for Children on anti-infectives. He chairs the RCPCH Standing Committee on Infection and Immunisation.
He co-chairs PENTA-ID, the EMA Level 1 recognised clinical trials network on antimicrobials in Europe. PENTA-ID provides paediatric CT expertise to the IMI ND4BB new antibiotic clinical trial development programme. He has developed the Paediatric Infectious Diseases Unit at St George’s into a recognised Centre of excellence for clinical care, teaching and research. He was appointed Professor of Paediatric Infectious Diseases in November 2010.
Professor Sharland’s principal research interest is optimising the best use of antimicrobials in children. He has a long standing interest in developing the evidence base for the use of all paediatric antimicrobials and has developed a clear research strategy using both cohort studies and clinical trials to improve the evidence base for antimicrobial prescribing. He leads a wide number of clinical projects in the UK and Europe with active NIHR/Charity/DG SANCO and FP7 funding.
Professor Sharland has consultancy expertise in engaging individuals, small research groups and larger established research entities, with the purpose of creating and leading national and international networks of scientific collaborators in the field of antimicrobial prescribing.
Fitchett, E. J. A., Seale, A. C., Vergnano, S., Sharland, M., Heath, P. T., Saha, S. K., . . . SPRING (Strengthening Publications Reporting Infection in Newborns Globally) Group. (2016). Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research.. Lancet Infect Dis, 16(10), e202-e213. doi:10.1016/S1473-3099(16)30082-2
Folgori, L., Bielicki, J., Ruiz, B., Turner, M. A., Bradley, J. S., Benjamin, D. K., . . . Sharland, M. (2016). Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review.. Lancet Infect Dis, 16(9), e178-e189. doi:10.1016/S1473-3099(16)00069-4
Versporten, A., Bielicki, J., Drapier, N., Sharland, M., Goossens, H., & ARPEC project group. (2016). The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children.. J Antimicrob
Bielicki, J. A., Sharland, M., Johnson, A. P., Henderson, K. L., Cromwell, D. A., & Antibiotic Resistance and Prescribing in European Children project. (2016). Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data.. J Antimicrob Chemother, 71(3), 794-802. doi:10.1093/jac/dkv397
Vergnano, S., Anderson, E., Seale, A., Heath, P. T., Saha, S., Sharland, M., . . . Lawn, J. (2015). Strengthening Publications Reporting Infections in Newborns Globally (SPRING) international survey on the criteria for reporting neonatal infections. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 20, 143-144. Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000360758800350&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=3511c51bff905dacd4f7fd11b0dd8b6d
Le Doare, K., Bielicki, J., Heath, P. T., & Sharland, M. (2015). Systematic Review of Antibiotic Resistance Rates Among Gram-Negative Bacteria in Children With Sepsis in Resource-Limited Countries.. J Pediatric Infect Dis Soc, 4(1), 11-20. doi:10.1093/jpids/piu014
Sharland M, Kendall H, Yeates D et al. Antibiotic prescribing in general practice and hospital admissions for peritonsillar abscess, mastoiditis, and rheumatic fever: a time trend analysis. BMJ 2005:331:328-329.
Menson EN, Walker AS, Sharland M, Wells C, Tudor-Williams G, Riordan FA, Lyall EG, Gibb DM; Collaborative HIV Paediatric Study Steering Committee. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ. 2006 May 20;332(7551):1183-7.
Sharland M; SACAR Paediatric Subgroup. The use of antibacterials in children: a report of the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) Paediatric Subgroup. J Antimicrob Chemother. 2007 Aug;60 Suppl 1:i15-26.
Thompson PL, Gilbert RE, Long PF, Saxena S, Sharland M, Wong IC. Has UK guidance affected general practitioner antibiotic prescribing for otitis media in children? J Public Health. 2008 Dec;30(4):479-86.
Thompson PL, Gilbert RE, Long PF, Saxena S, Sharland M, Wong IC. Effect of antibiotics for otitis media on mastoiditis in children: a retrospective cohort study using the United kingdom general practice research database. Pediatrics. 2009 Feb;123(2):424-30.
Saxena S, Bottle A, Gilbert R, Sharland M. Increasing short-stay unplanned hospital admissions among children in England; time trends analysis '97-'06. PLoS One. 2009 Oct 15;4(10)
PENTA - Paediatric European Network for the Treatment of AIDS
ESPID - European Society of Paediatric Infectious Diseases
ECDC – European Centre for Disease prevention and Control
Erasmus University, Department of Epidemiology
ESAC team at University of Antwerp
Health Protection Agency (UK)
University of London School of Pharmacy
Global Antimicrobial Resistance, Prescribing, and Efficacy in Children (GARPEC)
Modelling Antimicrobial Pharmacokinetics in Critically Ill Patients (ABdose)
Global Research in Paediatrics Research Network of Excellence (GRiP) - Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study (NAPPA)
Platform for European Preparedness against (Re) emerging Epidemics (PREPARE)
Innovative Medicines Initiative (IMI) – Combatting Bacterial Resistance in Europe-Carbapenem Resistance (COMBACTE-CARE)
CCG Wandsworth – Child Admission Bundle for Infection (CABIN2)
NIHR - Collaboration for Leadership in Applied Health Research and Care (CLAHRC) Infection Theme
Efficacy, safety and impact on antimicrobial resistance of duration and dose of antibiotic treatment for children with Community Acquired Pneumonia (CAP): a randomised controlled trial (CAP-IT)
Multi-centre randomised open label phase IIb study to compare the efficacy, safety and pharmacokinetics (PK) of an optimised dosing to a standard dosing regimen of vancomycin in neonates and infants aged less than 90 days with late onset bacterial sepsis known or suspected to be caused by Gram-positive microorganisms (NeoVanc)
EU funding bodies including: